文献速递免疫规划卫生政策与健康促进

法国2013至2017年白喉、破伤风、脊髓灰质炎和百日咳加强疫苗接种率:国家卫生系统真实世界数据分析

Vaccination coverage rates for Diphtheria, Tetanus, Poliomyelitis and Pertussis booster vaccination in France between 2013 and 2017: Learnings from an analysis of National Health System Real-World Data.
PubMed 文献 · Vaccine · 2020-12-21

该研究基于法国医保理赔数据1/97随机样本,估算2013至2017年各接种访视点的累计加强接种覆盖率。白喉-破伤风-脊髓灰质炎加强接种率逐年上升,2017年8岁达73.3%、15岁达75.6%,但各年龄组均不理想且成人更低;百日咳接种率亦上升,6岁与11-13岁访视点分别由16.4%升至63.8%、由50.3%升至61.2%;各访视点均存在延迟接种。

要点

  • 2013至2017年白喉-破伤风-脊髓灰质炎与百日咳加强接种率均上升,但各年龄组仍不理想
  • 2017年白喉-破伤风-脊髓灰质炎加强接种率随年龄下降,8岁73.3%、29岁46.6%、99岁11.0%
  • 2013年引入的6岁百日咳接种在2017年已较好落实,其他推荐变更落实缓慢或部分落实

核心结论

  • 2013至2017年法国白喉、破伤风、脊髓灰质炎和百日咳加强接种率上升,但各年龄组均不理想,成人人群更低。
  • 2013年引入的6岁百日咳接种在2017年已相对较好落实,其他推荐变更落实缓慢或部分落实。
  • 各接种访视点均观察到延迟接种。

研究设计与样本

  • 基于法国医保理赔数据1/97随机样本的观察性分析,估算2013至2017年累计加强接种覆盖率。
  • 研究对象为有资格接种加强针者,采用围绕推荐年龄(6、11-13、25、45、65、75、85、95岁)的较宽年龄组:5-8、10-15、21-29、41-49、61-69、71-79、81-89、91-99岁。

主要发现

  • 2017年白喉-破伤风-脊髓灰质炎加强接种率:8岁73.3%、15岁75.6%、29岁46.6%、49岁38.4%、69岁36.3%、79岁30.8%、89岁22.1%、99岁11.0%。
  • 百日咳接种率在各访视点均上升,6岁访视点由16.4%升至63.8%,11-13岁访视点由50.3%升至61.2%。
  • 各接种访视点均存在延迟接种。

关键数值与推荐

  • 2013年法国国家免疫规划实施变更,研究评估其后加强接种覆盖率演变及接种访视依从性。
  • 百日咳接种于2013年引入6岁接种,2017年该访视点接种率升至63.8%。

临床怎么用

  • 可利用医保理赔等真实世界数据持续监测各年龄加强接种覆盖率与延迟接种情况。
  • 针对成人加强接种率偏低及延迟接种问题,需加强接种提醒与依从性干预。
  • 评估免疫规划变更落实程度时,应分访视点追踪覆盖率变化而非仅看总体趋势。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Maintaining a high vaccination coverage rate (VCR) throughout the lifetime and complying with the National Immunization Program are essential to optimize the protection of the population. The study objectives were to evaluate the evolution of the VCRs and the compliance with the vaccination visits for the diphtheria, tetanus, poliomyelitis and pertussis boosters in France since the changes implemented in the 2013 National Immunization Program. METHODS: Cumulative booster VCRs were estimated at all vaccination visits, from 2013 to 2017, among persons eligible for a booster vaccination from a 1/97th random sample of French claims data. Broader age groups around the recommended ages by the vaccination schedule (6, 11-13, 25, 45, 65, 75, 85, 95y) were used: all persons aged 5 to 8, 10 to 15, 21 to 29, 41 to 49, 61 to 69, 71 to 79, 81 to 89 and 91 to 99. RESULTS: Over the study period, the diphtheria-tetanus-poliomyelitis booster VCRs increased, reaching in 2017: 73.3% at 8 years old, 75.6% at 15 years old, 46.6% at 29 years old, 38.4% at 49 years old, 36.3% at 69 years old, 30.8% at 79 years old, 22.1% at 89 years old and 11.0% at 99 years old. The pertussis VCRs were also increasing at all vaccination visits, in particular at the vaccination visits at 6 and 11-13 years old (from 16.4% to 63.8% and from 50.3% to 61.2%, respectively). Delayed vaccinations were observed at all vaccination visits. CONCLUSION: VCRs for Diphtheria, Tetanus, Poliomyelitis and Pertussis booster vaccination increased from 2013 to 2017 while remaining suboptimal across all ages and lower in the adult populations. The analysis also shows that the introduction in 2013 of a pertussis vaccination at 6 years of age was relatively well-established in 2017 while other changes in recommendations were slowly or partially implemented.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Marchal C, Belhassen M, Guiso N, et al. Vaccination coverage rates for Diphtheria, Tetanus, Poliomyelitis and Pertussis booster vaccination in France between 2013 and 2017: Learnings from an analysis of National Health System Real-World Data. Vaccine. 2020. PMID: 33357956. doi:10.1016/j.vaccine.2020.12.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。